Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Evotec and Bristol Myers Squib stick together on molecular glues
by Jessica Marshall
May 14, 2022
| A version of this story appeared in
Volume 100, Issue 17
Evotec and Bristol Myers Squibb are deepening their partnership on molecular glue degraders. Molecular glues are the next generation of targeted protein degraders, small molecules that lead a disease-causing protein to bind to an E3 ubiquitin ligase. This binding causes the protein to be degraded by cellular machinery. The companies will extend their partnership, started in 2018, by 8 years. Evotec will receive $200 million and milestone payments that could amount to $5 billion.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X